Department of Oriental Pharmaceutical Science, College of Pharmacy and Kyung Hee East-West Pharmaceutical Research Institute, Kyung Hee University, #1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea.
Neurobiol Learn Mem. 2011 Sep;96(2):306-14. doi: 10.1016/j.nlm.2011.06.004. Epub 2011 Jun 13.
Soluble oligomeric forms of amyloid beta (AβO) are regarded as a main cause of synaptic and cognitive dysfunction in Alzheimer's disease (AD) and have been a primary target in the development of drug treatments for AD. The present study utilized a mouse model of AD induced by intrahippocampal injection of AβO (10 μM) to investigate the effects of Gami-Chunghyuldan (GCD), a standardized multi-herbal medicinal formula, on the presentation of memory deficits and neurohistological pathogenesis. GCD (10 and 50mg/kg/day, 5 days, p.o.) improved AβO-induced memory impairment as well as reduced neuronal cell death, astrogliosis, and microgliosis in the hippocampus. In addition, GCD prevented AβO-triggered synaptic disruption and cholinergic fiber loss. These results suggest that GCD may be useful in the prevention and treatment of AD.
可溶性寡聚体形式的淀粉样蛋白β（AβO）被认为是阿尔茨海默病（AD）中突触和认知功能障碍的主要原因，并且一直是 AD 药物治疗开发的主要目标。本研究利用 AβO（10 μM）海马内注射诱导的 AD 小鼠模型，探讨了加味参苓白术散（GCD），一种标准化的多草药配方，对记忆缺陷表现和神经组织病理学发病机制的影响。GCD（10 和 50mg/kg/天，5 天，口服）改善了 AβO 诱导的记忆障碍，并减少了海马中的神经元细胞死亡、星形胶质细胞增生和小胶质细胞增生。此外，GCD 防止了 AβO 引发的突触破坏和胆碱能纤维丢失。这些结果表明，GCD 可能有助于 AD 的预防和治疗。
